ClinicalTrials.Veeva

Menu
F

Frenova Renal Research | New Jersey Kidney Care, LLC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LNP023
Clazakizumab
ANG-3070
Povetacicept
BI 685509

Parent organization

This site is a part of Frenova Renal Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 6 total trials

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who h...

Enrolling
Primary IgA Nephropathy
Drug: LNP023

This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a do...

Enrolling
Atherosclerotic Cardiovascular Disease
Atherosclerotic Cardiovascular Disease in Patients With ESKD
Drug: Placebo
Drug: CSL300

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserv...

Active, not recruiting
Immunoglobulin A Nephropathy
Drug: Placebo (matched to Povetacicept)
Drug: Povetacicept

Trial sponsors

Novartis logo
A
Boehringer Ingelheim logo
CSL Behring logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems